Biernacki Tamás, Bencsik Krisztina, Kincses Zsigmond Tamás, Sandi Dániel, Fricska-Nagy Zsanett, Faragó Péter, Vécsei László
Szegedi Tudományegyetem, Általános Orvostudományi Kar, Szent-Györgyi Albert Klinikai Központ, Neurológiai Klinika, Szeged.
MTA-SZTE Idegtudományi Kutatócsoport, Szeged.
Ideggyogy Sz. 2017 Nov 30;70(11-12):381-387. doi: 10.18071/isz.70.0381.
The aim of our case reports is to demonstrate the therapeutic use and possibilities one has with alemtuzumab, should it be used either as a first or second line therapy. Our first patient's disease in the beginning seemed to be benign. It was not the case however, over several years the diesase showed high activity both radiologically and clinically, she was treated with alemtuzumab as part of an esclationbased therapeutic strategy. The second patient's disease on the other hand showed formidable activity since the very beginning both radiologically and clinically. Therefore we were facing a very disastrous prognosis on the long run, accordingly he received alemtuzumab treatment very early into his illness.
我们病例报告的目的是展示阿仑单抗作为一线或二线治疗药物时的治疗用途和可能性。我们的首例患者的疾病起初看似良性。然而并非如此，数年来该疾病在放射学和临床上均表现出高活性，她接受了阿仑单抗治疗，这是基于逐步升级的治疗策略的一部分。另一方面，第二例患者的疾病从一开始在放射学和临床上就表现出严重的活性。因此从长远来看我们面临着非常糟糕的预后，相应地，他在患病早期就接受了阿仑单抗治疗。
